Keyword: Regeneron Pharmaceuticals
Despite Regeneron's rhetoric, analysts are pessimistic about growth prospects for its I-O drug Libtayo and new trial data didn't calm their fears.
Regeneron is sharpening Eylea's edge with prefilled syringes, a launch in diabetic retinopathy and tests of a higher dose to increase its durability.
As Pfizer advances a phase 3 rival to Regeneron and Sanofi's Dupixent, one analyst says it'll struggle to steal share because of side effects.
Regeneron has lost its edge in antibody development, so its growth potential may be limited, Analysts at SVBLeerink argue in a new report.
Phase 3 data for PCSK9-targeting RNAi drug inclisiran show it has the efficacy and clean safety profile to hang with Repatha and Praluent.
Sanofi and Regeneron have persuaded a judge that certain claims of two Amgen PCSK9 patents are invalid.
The Medicines Company's inclisiran, boasting a similar efficacy and safety profile but better convenience, could become the PCSK9 of choice, one analyst says.
Eli Lilly and Incyte's Olumiant has run up against safety hurdles in the past. But can they stop the drugmakers from adding another indication?
Pharma's second-quarter earnings season has come and gone, and we've ranked the players, from Regeneron's 20% sales hike to Teva's 8% drop.
Regeneron is humming along on the strength Eylea and Dupixent. Now, it’s expanding its production to keep up with that growth.